Changing the Game in
Drug Development and Patient Access

Model-informed Drug Development
Health Economics/Outcomes Research & Real World Evidence
Regulatory Science, Strategy & Services

Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug

Our Mission

Enable superior drug development and patient care decision-making through model-informed drug development, regulatory science, real world evidence and knowledge integration, thus optimizing R&D productivity, commercial value and patient outcomes.

Changing the Game in
Drug Development and Patient Access

Model-informed Drug Development
Health Economics/Outcomes Research & Real World Evidence
Regulatory Science, Strategy & Services

Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug

Our Mission

Latest from Certara

Blog

Certara Scientists Support TB Alliance’s Groundbreaking New Drug

Do Rigorous Science, Benefit the Patients & Have Fun: Insights from Regulatory Expert Eva Berglund

Optimize Immuno-oncology Drug Discovery and Development Using Quantitative Systems Pharmacology

In the Press

Certara Launches BaseCase Data Manager to Enhance Value-based Customer Presentations

Certara Introduces Version 19.6 of its D360 Scientific Informatics Platform

Certara Expands Evidence & Access Capabilities with Addition of Compass Consulting Team

Webinars

How to Optimize Your Drug Label Using Biosimulation Methodology

Using PopPK Modeling to Optimize Dosing in Patients with Organ Impairment

A New Method to Quantify Population Variability for Toxicity Testing

Changing the Game in Drug Development and Patient Access

Model-informed Drug Development Health Economics/Outcomes Research & Real World Evidence Regulatory Science, Strategy & Services

Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug

Our Mission

Latest from Certara

Changing the Game in
Drug Development and Patient Access

Model-informed Drug Development
Health Economics/Outcomes Research & Real World Evidence
Regulatory Science, Strategy & Services